KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Asset Utilization Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Asset Utilization Ratio for 15 consecutive years, with 0.51 as the latest value for Q1 2025.

  • On a quarterly basis, Asset Utilization Ratio changed N/A to 0.51 in Q1 2025 year-over-year; TTM through Mar 2025 was 0.51, a N/A change, with the full-year FY2024 number at 0.53, up 15.28% from a year prior.
  • Asset Utilization Ratio was 0.51 for Q1 2025 at Halozyme Therapeutics, up from 0.49 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.51 in Q1 2025 to a low of 0.36 in Q4 2022.
  • A 5-year average of 0.43 and a median of 0.42 in 2023 define the central range for Asset Utilization Ratio.
  • Biggest YoY gain for Asset Utilization Ratio was 37.88% in 2021; the steepest drop was 20.13% in 2021.
  • Halozyme Therapeutics' Asset Utilization Ratio stood at 0.39 in 2021, then fell by 8.0% to 0.36 in 2022, then increased by 28.4% to 0.46 in 2023, then rose by 6.17% to 0.49 in 2024, then grew by 4.83% to 0.51 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Asset Utilization Ratio are 0.51 (Q1 2025), 0.49 (Q4 2024), and 0.46 (Q4 2023).